View profile

FarmaKology Newsletter - Issue #82



September 7 · Issue #82 · View online

FarmaKology is a newsletter that brings you the latest news, research, job opportunities in the Pharma world, and much more! If you would like to be featured in the newsletter, sponsor an issue, or need anything, please feel free to get in touch with me at "".

Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to, and happy to have you featured on our newsletter (+12K Subscribers )!

FarmaKology Newsletter  - Issue #82
FarmaKology Newsletter - Issue #82
Today's Company
Checkmate Pharmaceuticals
Checkmate Pharmaceuticals
Checkmate Pharmaceuticals
Checkmate Pharmaceuticals is a clinical stage biotechnology company focused on developing proprietary technology to harness the power of the immune system to combat cancer. Checkmate’s product candidate, vidutolimod (CMP-001), is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body’s innate immune system to attack tumors in combination with other therapies. Checkmate’s goal is to leverage its proprietary technology to discover, develop and commercialize transformative treatments to fight cancer.
Merck , known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck’s anti-PD-1 therapy, has been approved by the National Medical Products Administration (NMPA) in China in combination with platinum- and fluoropyrimidine-based chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the esophagus or gastroesophageal junction (GEJ).
Travere Therapeutics, Inc. today announced a successful outcome from the Company’s Type A meeting with the U.S. Food and Drug Administration  in which alignment was reached on the Company’s plan to submit additional estimated glomerular filtration rate (eGFR) data from the ongoing pivotal Phase 3 DUPLEX Study of sparsentan in focal segmental glomerulosclerosis (FSGS) to support an application for accelerated approval in 2022.
Dr. Reddy’s Laboratories Ltd. announced the launch of the prescription drug Minoxidil topical solution USP 2% and 5% for the treatment of female pattern hair loss . Dr. Reddy’s will sell its products under the brand names Mintop™ 2% and Mintop Eva™ 5% respectively.
Peregrine Precision Systems Inc., an intellectual property technology company focused on enabling the cannabinoid industry to achieve its global potential, announces a new joint venture that aims to commercialize chemically synthesized rare cannabinoids and other natural ingredients.Jake Magolan, PhD, of McMaster University, and Synmedix have partnered with PPS to launch Naturally Synthetic Inc. This new start-up company will focus on leveraging its patent-pending processes to develop scalable chemical synthesis processes to manufacture rare cannabinoids and related phenolic natural products for the global R&D, pharmaceutical, and CPG communities.
Research & Study
Pharma Intelligence Podcasts - Pink Sheet Podcast: Top US FDA Vaccine Leaders Retire, COVID-19 Booster Shots, JAK Inhibitor Safety
Job Opportunities
Upcoming Webinar
Did you enjoy this issue?
In order to unsubscribe, click here.
If you were forwarded this newsletter and you like it, you can subscribe here.
Powered by Revue